



Prevalence of drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey



Collins Timire^{a,b}, John Z. Metcalfe^c, Joconiah Chirenda^d, Jerod N. Scholten^e, Barbara Manyame-Murwira^b, Mkhokheli Ngwenya^f, Ronnie Matambo^g, Kelvin Charambira^g, Herbert Mutunzi^b, Nico Kalisvaart^e, Charles Sandy^{b,*}

^a International Union Against Tuberculosis and Lung Disease (The Union), Paris, France

^b Ministry of Health and Child Care, National TB Control Program, Harare, Zimbabwe

^c Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco, CA, USA

^d University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe

^e KNCV Tuberculosis Foundation, The Hague, The Netherlands

^f World Health Organisation, Zimbabwe Country Office, Harare, Zimbabwe

^g The Union, Harare, Zimbabwe

ARTICLE INFO

Article history:

Received 20 May 2019

Received in revised form 9 July 2019

Accepted 21 July 2019

Corresponding Editor: Eskild Petersen, Aarhus, Denmark

Keywords:

Drug resistant TB

Previously treated TB

Zimbabwe

Rifampicin resistant TB

MDR

Gene Xpert

ABSTRACT

Objective: To determine the prevalence of resistance to rifampicin alone; rifampicin and isoniazid, and second-line anti-TB drugs among sputum smear-positive tuberculosis patients in Zimbabwe.

Design: A health facility-based cross-sectional survey.

Results: In total, 1114 (87.6%) new and 158 (12.4%) retreatment TB patients were enrolled. MTB was confirmed by Xpert MTB/RIF among 1184 (93%) smear-positive sputum samples. There were 64 samples with Xpert MTB/RIF-determined rifampicin resistance. However, two were rifampicin susceptible on phenotypic drug susceptibility testing. The prevalence of RR-TB was [4.0% (95% CI, 2.9, 5.4%), n = 42/1043] and 14.2% (95% CI, 8.9, 21.1%; n = 20/141) among new and retreatment patients, respectively. The prevalence of MDR-TB was 2.0% (95% CI, 1.3, 3.1%) and 6.4% (95% CI, 2.4, 10.3%) among new and retreatment TB patients, respectively. Risk factors for RR-TB included prior TB treatment, self-reported HIV infection, travel outside Zimbabwe for ≥one month (univariate), and age <15 years. Having at least a secondary education was protective against RR-TB.

Conclusion: The prevalence of MDR-TB in Zimbabwe has remained stable since the 1994 subnational survey. However, the prevalence of rifampicin mono-resistance was double that of MDR-TB.

© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

In the modern era, *Mycobacterium tuberculosis* (MTB) drug resistance is among the key challenges in ending TB (Mariandyshev and Eliseev 2017). In 2016, there were 600 000 new cases globally of multi-drug resistant tuberculosis (MDR-TB), defined as resistance to at least isoniazid and rifampicin (RIF), resulting in an estimated quarter-million annual deaths (World Health Organisation 2016). An estimated 92 629 MDR-TB cases (approximately 16% of the global burden) occurred on the African continent. However, 70% of these were not notified to health authorities, and only one-

half of the countries have completed a formal drug resistance survey (DRS) (World Health Organisation 2017).

Although neighboring South Africa reports the second highest absolute number of notified rifampicin-resistant cases in the world (second only to India) (World Health Organisation 2015b), and studies from the north of Zimbabwe have indicated a possible increase in MDR-TB prevalence among retreatment cases (Metcalfe et al. 2014), no nationally representative DRS has been performed in Zimbabwe. In 1994 a sub-national DRS was conducted in Zimbabwe and the prevalence of MDR-TB was 1.9% (95% CI, 1.1, 3.2) and 8.3% (95% CI, 2.9, 21.8) among new and retreatment TB patients, respectively (Mwinga 2006). At this time in the mid-1990s, HIV was rapidly becoming hyperendemic in Zimbabwe (Harries et al. 2001), and standard “short-course” 6-month regimens including RIF were yet to be adopted (this was done in 1994), antiretroviral drugs (ARVs) were unavailable, and it was

* Corresponding author at: Ministry of Health and Child Care, National TB Control Programme, 5th Floor Kaguvi Building, Cnr 4th/Central Avenue, Harare, Zimbabwe.
E-mail address: dr.c.sandy@gmail.com (C. Sandy).

questioned whether the societal costs of treating MDR-TB was worth control of the relatively small risk it presented (Schaaf et al. 1996). Since that time, there have been dramatic changes to the TB diagnostic and MDR-TB treatment landscapes; substantial increases in movement of economic and political migrants across borders in the Southern African region; and rapid and sustained scale-up of ARVs.

The best estimates of the burden of drug resistant TB in Africa require well-performed, population-based survey findings (Ismail et al. 2018). We undertook a cross-sectional survey in 2015–2016 to determine the prevalence among new and retreatment TB cases of Rifampicin-mono-resistance, MDR-TB, and resistance to second-line agents among those with MDR-TB. We also sought to assess the risk factors for rifampicin-resistant TB and to compare the MDR-TB estimate to that obtained in 1994 as a measure of the burden of drug-resistant TB.

Methods

Study design

A population-based cross-sectional study. Initially, patients in sampled health facilities were screened and diagnosed for TB using smear microscopy. Those who were smear-positive were asked to enroll in the survey as per WHO guidelines (World Health Organisation 2015a). The survey was conducted from August 2015–September 2016 on sputum-positive new and retreatment TB patients, regardless of age or HIV status, and not already on anti-TB therapy.

Since rifampicin resistance has conventionally been considered a proxy for MDR, and due to resource constraints, only Xpert MTB/RIF-determined rifampicin-resistant (RR) specimens proceeded to solid culture and first- and second-line DST. All patients whose samples had RR-TB strains on Xpert were re-interviewed to verify history of TB treatment.

Survey procedures

A survey questionnaire eliciting socio-demographic and clinical information (e.g. self-reported HIV status and history of TB) was administered to all consenting participants at enrolment. Two spot-sputum specimens were collected from consenting patients within two days of a smear-positive TB diagnosis. Sputum collection was done under the supervision of trained nurses. About 5 mL of spot-sputum specimens were collected in two 50 mL screw-capped falcon tubes, each containing 5 mL of Cetyl-Pyridium-Chloride. This was done to maintain the integrity of the sample in case of delays (of up to 30 days) in sample transportation to the National Reference Laboratory. Each tube was labelled with a unique patient identification number (PIN). The specimens were triple-packaged in zip-lock bags to minimize spillage and contamination and were stored at room temperature. A private courier transported the specimens to the National TB Reference Laboratory (NTBRL).

At the NTBRL, both specimens were vortexed for 15 s, pooled, and then split again. One specimen was tested using the Xpert MTB/RIF assay and the other was archived. A barcode reader was used to minimize transcription errors when inputting PIN numbers. In case of errors, assays were repeated using the remaining specimens from first specimens. Subsequent procedures were based upon Xpert MTB/RIF results: if RR-TB was not detected or MTB was not detected, no further procedures were performed. If RR-TB was detected, archived specimens were retrieved, decontaminated and the resultant sputum deposits were inoculated on LJ and pyruvate agar media according to standard operating procedures (Stop TB Partnership 2014). The media were incubated at 37 °C and growth of MTB was observed

weekly for up to 6 weeks. Part of the deposit was inoculated on LJ agar slants in 5 mL cryo-vials for shipment to a Supranational TB Reference Laboratory (SRL) in Antwerp, Belgium for external quality assurance. At the NTBRL, phenotypic culture and drug susceptibility testing (CDST) was done on LJ on all MTB positive isolates using the proportion method (Stop TB Partnership 2014). First-line DST was done for the drugs streptomycin, isoniazid, rifampicin and ethambutol (SIRE), and second-line DST for kanamycin, amikacin, ofloxacin, moxifloxacin and capreomycin. All the isolates were stored at –20 °C in cryo-vials with 10% glycerol. Hain Line Probe assay (LPA) (Hain LifeSciences, Nehren, Germany) was carried out on all cultures that failed to grow. Discordances between Xpert MTB/RIF RR-TB results and first-line phenotypic DST were resolved by conventional Sanger DNA sequencing of *rpoB* at the SRL. There was a 100% concordance in sensitivity and specificity between NTBRL and the SRL on the drugs kanamycin, capreomycin, ofloxacin and rifampicin. Sensitivity and specificity of isoniazid were 90% and 89%, respectively.

Sampling

Sampling was done as per WHO guidelines (World Health Organisation 2015a). First, probability proportional to size sampling was used to select 63 of 146 national TB diagnostic sites that were functional in 2012, and 20 of 56 national TB diagnostic sites that became functional between 2012 and 2014. Within each selected diagnostic site, consecutive eligible patients were enrolled until the required number of new cases for that site was reached, or the end of the survey period was reached.

As per WHO recommendations, sample size was calculated based on new patients only; retreatment patients were sampled on convenience. For new patients, a sample size of 677 was based on the following assumptions: (i) a total national notification of 12,405, based on 2012 programme data; (ii) an absolute precision of 1% at 95% confidence interval (CI); (iii) a *a priori* estimated prevalence of MDR-TB of 1.9%, based on the 1994 sub-national survey. After factoring in a design effect of two and accounting for possible losses of up to 20%, a minimum sample of 1625 new smear-positive patients was estimated.

Survey and data management

A survey management team and a steering committee were established to ensure smooth implementation of the survey. A pilot survey was conducted in 10% of the sites. Three teams from the national office were trained and they later provided on-site trainings to survey teams (TB nurses and laboratory staff) in different provinces starting with low-volume sites.

Each recruiting facility maintained a survey register which captured patient demographic and clinical data. Each patient had a PIN which was linked to all the survey tools (survey register, laboratory request form and NTBRL laboratory register). Xpert MTB/RIF and CDST results were reported to facilities to inform clinical management of patients. Quality of data was ensured through training of survey teams, cross-checking original forms during support visits by local teams and during data monitoring missions supported by staff from WHO and KNCV.

De-anonymised data were sent to the central level by a courier for double-data entry into the Census and Surveys Processing System (CSPRO) database by Zimbabwe National Statistics Agency staff. Electronic data were stored in a password-protected computer and backed-up on CDs stored in a locked-file cabinet. Source documents were stored in locked-file cabinets (Table 1).

Data analysis

Data were exported to SPSS version 20 (Chicago, Illinois, USA) for analysis. Categorical variables were summarized using frequencies. Continuous variables were summarized using means

Table 1

Number and (proportion) of participants who were enrolled in the Zimbabwe Drug Resistant survey by province, 2015–16.

Province	Total number notified during the survey period	Number of new patients	(%)	Expected number of new patients
Total	5279	1114	(65.5)	1700
Manicaland	298	135	(79.4)	170
Mashonaland Central	250	138	(73.8)	187
Mashonaland East	304	78	(65.5)	119
Mashonaland West	282	133	(65.2)	204
Matabeleland North	152	71	(54.9)	153
Matabeleland South	328	83	(46.4)	119
Midlands	300	136	(88.9)	153
Masvingo	258	93	(60.8)	153
Harare	2879	166	(46.5)	357
Bulawayo	228	81	(95.3)	85


and medians as appropriate. Weighted analysis of prevalence of RR-TB and MDR-TB were done using exact sampling probabilities to adjust for sampling error due to combining two sampling methods and the capping of patient recruitment at 12 months. Odds ratios and their 95% CI for factors associated with RR-TB were calculated using the stepwise logistic regression. Level of significance was set at $p < 0.05$.

Ethics

This survey was approved by the Medical Research Council of Zimbabwe and the Research Council of Zimbabwe. All the participants provided written informed consent/assent prior to enrolment and collection of sputum specimens.

Results

A total of 5279 sputum smear-positive patients were notified during the survey period. Of these, 1301 (24.6%) were initially enrolled and tested using Xpert MTB/RIF (Figure 1). Twenty-nine patients (2%) were excluded due to lack of survey forms and/or barcoding. The analysis population was 1272 patients: 1114 (87.6%) new and 158 (12.4%) retreatment (Figure 1). Of these, 766 (60.2%) were male, the median age was 34 years [(interquartile range (IQR), 27–42 years)], 699 (55.0%) self-reported a history of HIV infection, and 765 (60.1%) were recruited from urban clusters (Table 2). A total of 293 (23%) participants had a history of travel outside Zimbabwe of \geq one month's duration.

**Figure 1.** Flow of participants who were enrolled in the Zimbabwe DRS 2015–2016.

MDR-TB = multi-drug resistant TB; FQ = Fluoroquinolone; XDR-TB = extensively drug resistant TB; RMR = rifampicin mono-resistant TB; Poly-resistant = resistance to >one first-line anti-TB drug, other than both isoniazid and rifampicin.

Table 2
Socio-demographic and clinical characteristics of patients enrolled in the Zimbabwe TB drug resistant survey, 2015–2016.

Demographic characteristics	TB patients				Total	
	New		Retreatment		n	(%) ^a
	n	(%)	n	(%)		
Total	1114	(87.6)	158	(12.4)	1272	
Sex						
Male	668	(60.0)	98	(62.0)	766	(60.2)
Female	446	(40.0)	60	(38.0)	506	(39.8)
Age group						
<15	18	(1.6)	1	(0.6)	19	(1.5)
15–24	171	(15.4)	13	(8.2)	184	(14.5)
25–34	415	(37.3)	43	(27.2)	458	(36.0)
35–44	315	(28.3)	50	(31.6)	365	(28.7)
45–54	116	(10.4)	33	(20.9)	149	(11.7)
55–64	46	(4.1)	7	(4.4)	53	(4.2)
≥65	31	(2.8)	11	(7.0)	42	(3.3)
Unknown	2	(0.2)	0	(0)	2	(0.2)
HIV status						
Positive	580	(52.1)	119	(75.3)	699	(55.0)
Negative	492	(44.2)	34	(21.5)	526	(41.4)
Unknown	42	(3.7)	5	(3.2)	47	(3.6)
History of any travel outside Zimbabwe						
For ≥1 month	243	(21.8)	50	(31.6)	293	(23.0)
To South Africa	166	(14.9)	32	(20.3)	198	(15.6)
Other SADC countries	62	(5.6)	17	(10.8)	79	(6.2)
To other SADC countries	8	(0.7)	1	(0.6)	9	(0.7)
Unknown	7	(0.6)	0	(0.0)	7	(0.6)
Marital status						
Never married	229	(20.6)	22	(13.9)	251	(19.7)
Married	600	(53.9)	75	(47.5)	675	(53.1)
Divorced	177	(15.9)	33	(20.9)	210	(16.5)
Widowed	89	(8.0)	22	(13.9)	111	(8.7)
Unknown	19	(1.7)	6	(3.8)	25	(2.0)
Level of education						
None	39	(3.5)	4	(2.5)	43	(3.4)
Primary	312	(28.0)	46	(29.1)	358	(28.1)
Secondary	700	(62.8)	94	(59.5)	794	(62.4)
Tertiary	55	(4.9)	13	(8.2)	68	(5.3)
Missing	8	(0.7)	1	(0.6)	9	(0.7)
Cluster location						
Urban	671	(60.2)	94	(59.5)	765	(60.1)
Rural	443	(39.8)	64	(40.5)	507	(39.9)

SADC = Southern Africa Development Community; TB = tuberculosis.

^a Column percentages.

Bacteriologic results

Of the 1272 valid Xpert MTB/RIF assays, 1184 (93.1%) detected MTB. There were 44 (3.5%) new and 20 (1.6%) retreatment TB patients who had Xpert-determined RR-TB. Of these 64, 50 (78.1%) successfully grew on culture at the NTBRL. First and second-line phenotypic DST confirmed RR-TB in 48 (96%), while two cultures (4%) were susceptible to all the first-line drugs (SIRE) according to phenotypic CDST, Hain LPA (at the NTBRL), and *rpoB* gene sequencing at the SRL. Twenty-five cultures [(52.1%) (95% CI, 38.3, 65.5)] had MDR-TB; 20 demonstrated rifampicin mono-resistance (RMR); three had poly-resistance and two were rifampicin susceptible. Of the 25 MDR-TB cultures, one (4.0%) demonstrated fluoroquinolone and aminoglycoside resistance in addition to MDR (XDR-TB).

The crude prevalence of RR-TB was [4.0% (95% CI, 2.9, 5.4%), n = 42/1043] and [14.2% (95% CI, 8.9, 21.1%), n = 20/141] among new and retreatment patients, respectively. The crude prevalence of MDR-TB was 2.0% [(95% CI, 1.3, 3.1%)] and [6.4% (95% CI, 2.4,

10.3%)] among new and retreatment TB patients, respectively. Among new patients, the weighted prevalence of RR-TB and MDR-TB were [4.6% (95% CI, 3.0, 6.2)] and [1.8% (95% CI, 1.0, 2.5)] respectively.

Risk factors for RR-TB

In univariate analysis, a history of travel outside Zimbabwe for ≥one month [(odds ratio [(OR = 1.74, 95% CI, 1.02, 2.97)] had increased odds of RR-TB. In multivariate analysis, HIV-positivity [adjusted odds ratio (aOR) = 2.12 (95% CI, 1.09, 4.05)], age <15 years [aOR = 6.37 (95% CI, 1.51, 26.87)], and a previous history of TB treatment [aOR = 3.53 (95% CI, 1.86, 6.25)] were associated with RR-TB, while having at least a secondary education was protective [(aOR = 0.52; 95% CI, 0.29, 0.97)] (Table 3). After stratifying by type of TB patient, a positive HIV status [aOR = 2.19; 95% CI, 1.07, 4.46)] and history of travel outside Zimbabwe [aOR = 2.05; 95% CI, 1.05, 4.03]] were significantly associated with RR-TB among new patients (Table 4).

Table 3

Risk factors for rifampicin resistance among patients diagnosed with smear-positive sputum during the TB drug resistant survey, Zimbabwe (2015–2016).

Variable	Total	RR-TB detected		OR (95% CI)	aOR 95% CI
		n	(%) ^a		
	1184	62	(5.2)		
Sex					
Female	466	20	(4.3)	Ref	Ref
Male	718	42	(5.8)	1.38 (0.78, 2.52)	1.43 (0.69, 2.46)
Age group					
<15	18	4	(22.2)	6.90 (1.80, 26.45) ^b	6.37 (1.51, 26.87) ^b
15–24	176	7	(4.0)	Ref	Ref
25–34	431	19	(4.4)	1.11 (0.46, 2.70)	0.96 (0.38, 2.42)
35–44	337	22	(6.5)	1.68 (0.68, 4.77)	1.25 (0.46, 3.27)
45–54	128	5	(3.6)	0.91 (0.28, 2.92)	0.52 (0.16, 1.75)
55–64	48	3	(6.2)	1.61 (0.40, 6.47)	1.04 (0.24, 4.42)
≥65	34	2	(5.9)	0.51 (0.30, 7.60)	0.90 (0.16, 4.98)
Level of education					
Primary and less	363	27	(7.4)	Ref	Ref
Secondary and above	813	34	(4.2)	0.54 (0.31, 0.95) ^b	0.52 (0.29, 0.97) ^b
Unknown	8	1	(12.5)	1.78 (0.21, 14.99)	2.83 (0.30, 27.08)
Cluster location					
Urban	714	37	(5.2)	Ref	
Rural	470	25	(5.3)	1.03 (0.58, 1.78)	0.90 (0.54, 1.71)
HIV status					
Negative	508	14	(2.8)	Ref	Ref
Positive	632	46	(7.3)	2.77 (1.46, 5.52) ^b	2.12 (1.09, 4.05) ^b
Unknown	44	2	(4.5)	1.68 (0.18, 7.70)	1.34 (0.29, 6.24)
History of any travel outside Zimbabwe					
for ≥1 month	281	22	(7.8)	1.74 (1.02, 2.97) ^b	1.69 (0.95, 2.99)
To South Africa	190	17	(8.9)	1.55 (0.55, 4.36)	1.49 (0.57, 4.39)
To other SADC countries	270	21	(7.8)	0.84 (0.10, 6.91)	0.87 (0.15, 6.42)
Treatment history					
New	1043	42	(4.0)	Ref	Ref
Retreatment	141	20	(14.2)	3.94 (2.11, 7.11) ^b	3.53 (1.86, 6.25) ^b

OR = odds ratio; HIV = human immune-deficiency virus; aOR = adjusted odds ratio; SADC = Southern Africa Development Community; Ref = reference.

^a Row percentages.^b Significant.**Table 4**

Factors associated with rifampicin resistance, among patients diagnosed with smear-positive sputum during the TB drug resistant survey, Zimbabwe (2015–2016), disaggregated by type of TB patient.

Risk factors	Type of TB case					
	New (n = 1043)		Retreatment (n = 141)		Total (n = 1184)	
	aOR	95% CI	aOR	95% CI	aOR	95% CI
Sex						
Female	1.08	0.55, 2.12	2.16	0.68, 6.82	1.43	0.69, 2.46
Male	Reference		Reference		Reference	
Age group						
<15	8.59	1.47, 50.04 ^a	–		6.37	1.51, 26.87 ^a
15–24	Reference		Reference		Reference	
25–34	1.62	0.45, 5.84	0.28	0.05, 1.48	0.96	0.38, 2.42
35–44	2.44	0.68, 8.77	0.29	0.06, 1.40	1.25	0.46, 3.27
45–54	0.64	0.10, 4.06	0.19	0.03, 1.11	0.52	0.16, 1.75
55–64	2.43	0.45, 13.27	N/A		1.04	0.24, 4.42
≥65	1.91	0.19, 19.80	0.20	0.02, 2.56	0.90	0.16, 4.98
Level of education						
≤Primary	Reference		Reference		Reference	
≥Secondary	0.52	0.27, 1.02	0.75	0.21, 2.67	0.52	0.29, 0.97 ^a
Unknown	5.11	0.51, 51.25	–		2.83	0.30, 27.08
HIV status						
Negative	Reference		Reference		Reference	
Positive	2.19	1.07, 4.46 ^a	1.76	0.44, 7.09	2.12	1.09, 4.05 ^a
Unknown	0.89	0.11, 7.25	2.72	0.21, 34.71	1.34	0.29, 6.24
History of travel outside Zimbabwe						
for ≥ 1 month	2.05	1.05, 4.03 ^a	1.09	0.37, 3.16	1.69	0.95, 2.99
Treatment history						
New						Reference
Re-treatment					3.53	1.86, 6.25 ^a

OR = odds ratio; HIV = human immune-deficiency virus; aOR = adjusted odds ratio. – = undefined.

^a Significant.

Discussion

This first nationally representative TB-DRS survey for Zimbabwe was conducted following significant socio-political and epidemiological changes in the country. We demonstrated that the prevalence of MDR-TB has remained stable since 1994 though the prevalence of RR-TB is now double that of MDR-TB. We also observed that the factors associated with RR-TB were a previous history of TB, HIV positivity, age <15 years, lower than secondary education and a stay outside Zimbabwe for \geq a month.

The observed prevalence of MDR-TB was consistent with prevalence reported from South Africa [(2.1% (95% CI, 1.5, 2.7) and 4.6% (CI, 95%: 3.2, 6.0) among new and previously treated patients, respectively in the 2012–2014 survey] and Botswana [(2.5%, 95% CI, 1.6, 3.7) and 6.6%, 95% CI, 3.3, 11.7) among new and previously treated patients during 2007–2008)] (National Institute for Communicable Diseases 2014; Menzies et al. 2014), but was lower than prevalence recorded in both Lesotho [(3.1% (95% CI, 2.1, 4.3) and (12.8% (95% CI, 8.8, 18.2)] among previously treated patients and Namibia [(3.8% (95% CI, 2.8, 5.1) and (16.4% (95% CI, 12.9, 20.6)] among previously treated patients for the survey carried out in 2008–2009 (Maama-Maime et al. 2015; Ministry of Health and Social Services: National Tuberculosis and Leprosy Programme 2012). The increase in the prevalence of RR-TB could be attributed to a high proportion of RMR observed in this study. This may be due to acquired resistance to rifampicin. Studies have shown associations between RMR and factors like a positive HIV status, previous histories of TB, use of antifungals and use of rifabutin (Meyssonier et al. 2014; Ridzon et al. 2013; Villegas et al. 2016). The association between a positive HIV-status and RR-TB could be attributed to acquired drug resistance resulting from “preferential adherence” to antiretroviral drugs at the expense of anti-TB drugs among TB co-infected patients as reported in a previous qualitative study (Daftary et al., 2014).

The findings that the previous histories of TB and stay outside Zimbabwe for \geq 1 month (bivariate analysis) were associated with RR-TB were not surprising. The latter may stem from the fact that most Zimbabweans go to neighbouring, high TB-burden countries as economic emigrants and living conditions there may foster acquisition of RR-TB. Neither DRS surveys in southern Africa nor studies, including systematic reviews, found any association between MDR-TB and HIV infection (Lukoye et al. 2015; National Institute for Communicable Diseases 2014; Maama-Maime et al. 2015; Ministry of Health and Social Services: National Tuberculosis and Leprosy Programme 2012; Menzies et al. 2014).

We do not know the reasons why attainment of secondary education was protective against RR-TB. Perhaps, attainment of secondary education is associated with better socio-economic status and positive health behavioral traits. By contrast, a study done in China showed that attainment of high school was a risk factor for RR-TB (Yang et al. 2015). Drug resistant surveys from southern Africa did not assess the relationship between education and risk of RR-TB. Studies from high-income countries failed to show the relationship between education and risk of RR-TB. Thus more research is needed to investigate this relationship.

This study enrolled more patients from urban than from rural areas, a consistent finding with program data in which high notifications are recorded in urban centers. This exposes geographical health inequities despite a similar burden of MTB between rural and urban centers as evidenced in this study and the 2014 Zimbabwe National TB prevalence survey (Ministry of Health and Child Care 2014).

This survey had some limitations. First, in adopting sputum smear-positivity as our starting point, we invariably underreported RR-TB in this high HIV-burden setting given that children and HIV-positive patients often produce pauci-bacillary specimens. Second,

all sputum specimens in which RR-TB was not detected did not undergo CDST. Thus, the prevalence of isoniazid mono-resistance is unknown, though it is known to be rising elsewhere in the southern Africa Development Community (SADC) (Variava and Martinson 2018; National Institute for Communicable Diseases 2014). Future DRS surveys should determine the prevalence of isoniazid-mono resistance. Third, 6% of new and 11% of retreatment sputum smear-positive specimens tested Xpert MTB/RIF-negative, raising the possibility of non-tuberculosis mycobacteria (NTM). Indeed the previous adopting sputum smear-positivity as our starting point, we invariably underreported RR-TB in this high HIV-burden setting given that children and HIV-positive patients often produce pauci-bacillary specimens. Second, all sputum specimens in which RR-TB was not detected did not undergo CDST. Thus, the prevalence of isoniazid mono-resistance is unknown, though it is known to be rising elsewhere in the southern Africa Development Community (SADC) (Variava and Martinson 2018; National Institute for Communicable Diseases 2014). Future DRS surveys should determine the prevalence of isoniazid-mono resistance. Third, 6% of new and 11% of retreatment sputum smear-positive specimens tested Xpert MTB/RIF-negative, raising the possibility of non-tuberculosis mycobacteria (NTM). Indeed the prevalence of NTM is very high in Zimbabwe. During the 2014 TB prevalence survey the prevalence of NTM was estimated to be 16.9% (964/5705) of all the survey presumptive TB cases. Of the NTM isolates obtained in a convenient sample of specimens collected during the 2014 TB prevalence survey, the prevalence of clinically significant NTM such as *Mycobacteria Avium* complex (MAC) was 51.5% (41/81) (Chin'ombe et al. 2016; Ministry of Health and Child Care 2014). Fourth, HIV status was obtained by self-report. Incorporation of HIV testing in TB-DRS surveys could have provided crucial information for the NTP on the relationship between HIV and drug-resistant TB (World Health Organization 2015). Lastly, we did not do multiple imputation to control for bias on the results for 14 samples that did not have DST results (no culture growths or contaminated cultures) since our data were robust. However, it would have been a useful exercise to compare potential differences in results between our models and the imputation models.

Several programmatic implications arise from this study. First, there is need to improve early and universal access to DST (in Zimbabwe and elsewhere in SADC) for at least rifampicin, in line with the WHO End TB strategy (STOP TB Partnership 2015). Second, since isoniazid prophylactic therapy (IPT) has been scaled up in Zimbabwe with \geq 20,000 PLHIV having been started on IPT by December 2015 and IPT completion rates of \geq 89% have been attained (Takarinda et al. 2017, 2019), and within the context of South African isoniazid-mono resistance of [4.9%, 95% CI: 4.1%–5.8%], (National Institute for Communicable Diseases 2014) estimating the prevalence of and continued monitoring of isoniazid mono-resistance should be prioritized in Zimbabwe. Third, although sample size was small and should be interpreted as hypothesis-generating, we noted an increased risk of RR-TB among older children and adolescents, and warrants additional studies examining the determinants of childhood RR-TB in Zimbabwe. Lastly, we could not follow up on the treatment outcomes of this group.

In conclusion, the prevalence of MDR-TB in Zimbabwe has remained stable since the 1994 subnational survey.

Author contributions

CS, RM, MN, JNS, JC, HM, KC, NK, BMM designed the study. JNS, JC, KC, CT, RM, MN, CS, NK analysed the data. CT, JZM and CS drafted the manuscript. BMM processed the specimens. All authors read and approved the manuscript for intellectual content. All the authors read and approved the final manuscript.

Conflict of interest statement

None declared.

Funding

This survey was funded by the USAID's Challenge TB through the World Health Organisation. The funders had no role in the design and interpretation of the findings.

Acknowledgements

A special thank you goes to the participants who volunteered to take part in the drug resistant survey. Thanks are also due to all staff who worked tirelessly to make this survey a success.

References

- Chin'ombe Nyasha, Muzividzi Boniface, Munemo Ellen, Nziramasanga Pasipanodya. Molecular identification of nontuberculous mycobacteria in humans in Zimbabwe Using 16S ribosequencing. *Open Microbiol J* 2016;10:113–23, doi: <http://dx.doi.org/10.2174/1874285801610010113>.
- Daftary Amrita, Padayatchib Nesri, Max O'Donnellb C. Preferential adherence to antiretroviral therapy over tuberculosis (TB) treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. *Glob Public Health* 2014;9(9):1107–16, doi: <http://dx.doi.org/10.1080/17441692.2014.934266>.
- Harries Anthony D, Hargreaves James, Kemp JR, Jindani Amina, Enarson DA, Maher Dermot, et al. Deaths from tuberculosis in Sub-Saharan African countries with a high prevalence of HIV-1. *Lancet* 2001;357(9267):1519–23, doi: [http://dx.doi.org/10.1016/S0140-6736\(00\)04639-0](http://dx.doi.org/10.1016/S0140-6736(00)04639-0).
- Ismail Nazir Ahmed, Mvusi Lindiwe, Nanoo Ananta, Dreyer Andries, Omar Shaheed V, Babatunde Sanni, et al. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. *Lancet Infect Dis* 2018;18(7):779–87, doi: [http://dx.doi.org/10.1016/S1473-3099\(18\)30222-6](http://dx.doi.org/10.1016/S1473-3099(18)30222-6).
- Lukoye Deus, Ssengooba Willy, Musisi Kenneth, Kasule George W, Cobelens Frank GJ, Joloba Moses, et al. Variation and risk factors of drug resistant tuberculosis in Sub-Saharan Africa: a systematic review and meta-analysis. *BMC Public Health* 2015;15(1):1–13, doi: <http://dx.doi.org/10.1186/s12889-015-1614-8>.
- Maama-Maime Llang B, Mareka Mathabo, Ershova Julia V, Tlali Thabong E, Kao Kekeletso, Phalatse Mamakhetha, et al. Antituberculosis drug resistance survey in Lesotho, 2008–2009: lessons learned. *PLoS One* 2015;10(7):2008–9, doi: <http://dx.doi.org/10.1371/journal.pone.0133808>.
- Mariandyshv Andrei, Eliseev Platon. Drug-resistant tuberculosis threatens WHO's end-TB strategy. *Lancet Infect Dis* 2017;17(7):674–5, doi: [http://dx.doi.org/10.1016/S14733099\(17\)30246-3](http://dx.doi.org/10.1016/S14733099(17)30246-3).
- Menzies HJ, Moalosi G, Anisimova V, Gammino V, Sentele C, Bachhuber MA, et al. Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth national drug resistance survey. *Int J Tuberc Lung Dis* 2014;18(9):1026–33, doi: <http://dx.doi.org/10.5588/ijtld.13.0749>.
- Metcalf JZ, Makumbirofa S, Makamure B, Sandy Charles, Bara W, Mungofa S, et al. Drug-resistant tuberculosis in high-risk groups, Zimbabwe. *Emerg Infect Dis* 2014;20(1):135–7.
- Meyssonier Vanina, Van Bui Thuy, Veziris Nicolas, Jarlier Vincent, Robert Jérôme. Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis. *BMC Infect Dis* 2014;14(January):18, doi: <http://dx.doi.org/10.1186/1471-2334-14-18>.
- Ministry of Health and Child Care. Zimbabwe national population-based tuberculosis prevalence survey Harare, Zimbabwe. 2014.
- Ministry of Health and Social Services: National Tuberculosis and Leprosy Programme. Namibia national tuberculosis drug resistance survey (2008–2009) Windhoek, Namibia. 2012.
- Mwinga Alwyn. Drug-resistant tuberculosis in Africa. *Ann N Y Acad Sci* 2006;106–12, doi: <http://dx.doi.org/10.1111/j.1749-6632.2001.tb11366.x>.
- National Institute for Communicable Diseases. South African tuberculosis drug resistance survey 2012–14 Pretoria, South Africa. 2014.
- Ridzon R, Whitney CG, McKenna MT, Taylor JP, Ashkar SH, Nitta AT, et al. Risk factors for rifampin mono-resistant tuberculosis. *Am J Respir Crit Care Med* 2013;157(6):1881–4, doi: <http://dx.doi.org/10.1164/ajrccm.157.6.9712009>.
- Schaaf HS, Botha P, Beyers N, Gie RP, Vermulen HA, Groenwald P, et al. The 5-year outcome of multidrug resistant tuberculosis patients in the Cape Province of South Africa. *Trop Med Int Health* 1996;1(5):718–22.
- Stop TB Partnership. Mycobacteriology laboratory manual Geneva, Switzerland. 2014.
- STOP TB Partnership. The paradigm shift 2016–2020: global plan to end TB Geneva, Switzerland. 2015.
- Takarinda KC, Choto RC, Mutasa-Apollo T, Chakanyuka-Musanhu C, Timire C, Harries AD. Scaling up isoniazid preventive therapy in Zimbabwe: has operational research influenced policy and practice?. *Public Health Action* 2019;8(4):218–24, doi: <http://dx.doi.org/10.5588/pha.18.0051>.
- Takarinda KC, Harries AD, Choto RC, Mutasa-Apollo T, Chakanyuka-Musanhu C. Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe. *Public Health Action* 2017;7(1):55–60, doi: <http://dx.doi.org/10.5588/pha.16.0102>.
- Variava Ebrahim, Martinson Neil. Drug-resistant tuberculosis: the rise of the monos. *Lancet Infect Dis* 2018;18(7):705–6, doi: [http://dx.doi.org/10.1016/S1473-3099\(18\)30247-0](http://dx.doi.org/10.1016/S1473-3099(18)30247-0).
- Villegas Leonela, Otero Larissa, Sterling Timothy R, Huaman Moises A, Van der Stuyft Patrick, Gotuzzo Eduardo, et al. Prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru. *PLoS One* 2016;11(4)e0152933, doi: <http://dx.doi.org/10.1371/journal.pone.0152933>.
- World Health Organisation. Guidelines for surveillance of drug resistance in tuberculosis. Geneva, Switzerland. 5th ed. 2015. <https://www.doi.org/WHO/HTM/TB/2015.13>.
- World Health Organisation. Global tuberculosis report 2015 Geneva, Switzerland. 2015.
- World Health Organisation. Global TB report 2016 Geneva, Switzerland. 2016.
- World Health Organisation. Global tuberculosis report 2017 Geneva, Switzerland. 2017.
- World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 5th edition 2015 Geneva, Switzerland.
- Yang Xiujun, Yuan Yanli, Pang Yu, Wang Bo, Bai Yunlong, Wang Yanhua, et al. The burden of MDR/XDR tuberculosis in coastal plains population of China. *PLoS One* 2015;10(2):1–12, doi: <http://dx.doi.org/10.1371/journal.pone.0117361>.